An experimental "vaccine" for celiac disease is set to be tested in a new clinical trial to see if the treatment can protect patients with the condition from the effects of eating gluten — or, in other words, allow those patients to eat gluten safely.

The treatment, called Nexvax2 and made by the biotech company ImmusanT Inc., is a type of immunotherapy that aims to "reprogram" the immune system to be tolerant of gluten, the researchers said.

Celiac disease is a condition in which people's immune systems react abnormally to gluten — a protein found in wheat, rye and barley — and this reaction damages the lining of the small intestine. The condition affects about 1 out of every 100 people in the United States.

Currently, the only way to manage ...

The thalidomide ordeal that started in the 1950s is a tragic case of what happens when key players in the scientific community dismiss or ignore widespread correlations among two or more coinciding events. In the mid-century, a German pharmaceutical company named Chemie Grunenthal discovered and developed a synthetic sedative called thalidomide that was used to treat sleeplessness, and reduce morning sickness and nausea commonly experienced by pregnant women. While most countries around the world embraced and sold the product for a short period of time, including Canada, the United States’ Food and Drug Administration at the time, which was headed by a Canadian-born medical doctor named Dr. Kelsey, refused to approve its use in the countr ...